Modulation of anxiety behavior in the elevated plus maze using peptidic oxytocin and vasopressin receptor ligands in the rat

Journal of Psychopharmacology

Volumn 26, Issue 4, 2012, Pages 532-542

  Mak, Plato ^a   Broussard, Christina ^a   Vacy, Kristina ^a   Broadbear, Jillian H ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Anxiolytic; atosiban; carbetocin; desmopressin; diazepam; elevated plus maze; oxytocin; Sprague Dawley rat; vasopressin

Indexed keywords

ANGIOTENSIN II; ARGIPRESSIN; ARGIPRESSIN RECEPTOR; ATOSIBAN; CARBETOCIN; DESMOPRESSIN; DIAZEPAM; DUROTOCIN; LIGAND; NEUROPEPTIDE; OXYTOCIN; OXYTOCIN RECEPTOR; PAMLIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VASOPRESSIN RECEPTOR;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIURESIS; ANXIETY; ARTICLE; BEHAVIOR CHANGE; CHRONIC DRUG ADMINISTRATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG TARGETING; ELEVATED PLUS MAZE; EXPERIMENTAL TEST; FLUID INTAKE; LOW DRUG DOSE; MALE; MAZE TEST; MOOD; NEUROMODULATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SINGLE DRUG DOSE; SPRAGUE DAWLEY RAT; SYSTEMIC THERAPY; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; DEAMINO ARGININE VASOPRESSIN; DIAZEPAM; LIGANDS; MALE; MAZE LEARNING; OXYTOCIN; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OXYTOCIN; RECEPTORS, VASOPRESSIN; VASOTOCIN;

EID: 84860188488     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111416687     Document Type: Article

References (64)

1. Amico JA, Mantella RC, Vollmer RR, et al. Anxiety and stress fresponses in female oxytocin deficient mice. J Neuroendocrinol. 2004 ; 16: 319-324
2. Arletti R, Bertolini A. Oxytocin acts as an antidepressant in two animal models of depression. Life Sci. 1987 ; 41: 1725-1730
3. Arletti R, Benelli A, Poggioli R, et al. Aged rats are still responsive to the antidepressant and memory-improving effects of oxytocin. Neuropeptides. 1995 ; 29: 177-182
4. Bale TL, Davis AM, Auger AP, et al. CNS region-specific oxytocin receptor expression: importance in regulation of anxiety and sex behavior. J Neurosci. 2001 ; 21: 2546-2552
5. Beringer K, Broadbear JH. Oxytocin as a mediator of the unique interoceptive effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") in the rat. Aust Psychol Soc Conf Proc. 2008 ; 43: 31-35
6. Bhattacharya SK, Bhttacharya A, Chakrabarti A. Anxiogenic activity in intraventricularly administered arginine vasopressin in the rat. Biogenic Amines. 1998 ; 14: 367-385
7. Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ. Profound impairment in social recognition and reduction in anxiety-like behaviour in vasopressin V1a receptor knockout mice. Neuropsychopharmacology. 2004 ; 29: 483-493
8. Bleickardt CJ, Mullins DE, MacSweeney CP, et al. Characterisation of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior. Psychopharmacology. 2009 ; 202: 711-718
9. Blume A, Bosch OJ, Miklos S, Torner L, Wales L, Waldherr M, Neumann ID. Oxytocin reduces anxiety via ERK1/2 activation: local effect within the rat hypothalamic paraventricular nucleus. Eur J Neurosci. 2008 ; 27: 1947-1956
10. Broadbear JH, Tunstall B, Beringer K. Examining the role of oxytocin in the interoceptive effects of 3,4-methylenedioxy-methamphetamine (MDMA, "ecstasy") using a drug discrimination paradigm in the rat. Addiction Biol. 2011 ; 16: 202-214
11. Chaviaras S, Mak P, Ralph D, Krishnan L, Broadbear JH. Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test. Psychopharmacology. 2010 ; 210: 35-43
12. Cruz APM, Frei F, Graeff FG. Ethopharmacological analysis of rat behavior on the elevated plus maze. Pharmacol Biochem Behav. 1994 ; 49: 171-176
13. Dawson GR, Tricklebank MD. Use of the elevated plus maze in the search for novel anxiolytic agents. TiPS. 1995 ; 16: 33-36
14. Detke MJ, Johnson J, Lucki I. Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol. 1997 ; 5: 107-112
15. Engin E, Treit D. Dissociation of the anxiolytic-like effects of Avpr1a and Avpr1b receptor antagonists in the dorsal and ventral hippocampus. Neuropeptides. 2008 ; 42: 411-421
16. Engstrom T, Barth T, Melin P, et al. Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol. 1998 ; 355: 203-210
17. Ermisch A, Ruhle HJ, Landgraf R, Hess J. Blood-brain barrier and peptides. J Cereb Blood Flow Metab. 1985 ; 5: 350-357
18. File SE, Mabbutt PS, Hitchcott PK. Characterisation of the phenomenon of "one-trial tolerance" to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze. Psychopharmacology. 1990 ; 102: 98-101
19. File SE, Zangrossi H, Viana M, Graeit FG. Trial 2 in the elevated plus-maze: a different form of fear?. Psychopharmacology. 1992 ; 111: 491-494
20. Frank E, Landgraf R. The vasopressin system-from antidiuresis to psychopathology. Eur J Pharmacol. 2008 ; 583: 226-242
21. Frasch A, Zetzsche T, Steiger A, et al. Reduction of plasma oxytocin levels in patients suffering from major depression. Adv Exp Med Biol. 1995 ; 395: 257-258
22. Friedman H, Abernethy DR, Greenblatt DJ, Shader RI. The pharmacokinetics of diazepam and desmethyldiazepam in rat brain and plasma. Psychopharmacology. 1986 ; 88: 267-270
23. Gibbs DM. Vasopressin and oxytocin: hypothalamic modulators of the stress response: a review. Psychoendocrinology. 1986 ; 11: 131-140
24. Gimpl G, Postina R, Fahrenholz F, et al. Binding domains of the oxytocin receptor for the selective oxytocin receptor antagonist barusiban in comparison to the agonists oxytocin and carbetocin. Eur J Pharmacol. 2005 ; 510: 9-16
25. Greenblatt DJ, Allen MD, Harmatz JS, Shader RI. Diazepam disposition determinants. Clin Pharmacol Ther. 1980 ; 27: 301-312
26. Griebel G, Rodgers RJ, Perrault G, et al. Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacol Biochem Behav. 1997 ; 57: 817-827
27. Griebel G, Simiand J, Gal CS, et al. Anxiolytic-and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci USA. 2002 ; 99: 6370-6375
28. Handley SL, Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of 'fear'-motivated behaviour. Naunyn-Schmiedeberg's Arch Pharmacol. 1984 ; 327: 1-5
29. Huber D, Veinante P, Stoop R. Vasopressin and OT excite distinct neuronal populations in the central amygdala. Science. 2005 ; 308: 245-248
30. Insel TR, O'Brien DJ, Leckman JF. Oxytocin, vasopressin, and autism: is there a connection?. Biol Psychiatry. 1999 ; 45: 145-157
31. Jung ME, Wallis CJ, Gatch MB, et al. Abecarnil and alprazolam reverse anxiety-like behaviors induced by ethanol withdrawal. Alcohol. 2000 ; 21: 161-168
32. Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci. 2005 ; 25: 11489-11493
33. Klenerova V, Krejci I, Sida P, Hlinak Z, Hynie S. Modulatory effects of oxytocin and carbetocin on stress-induced changes in rat behavior in the open-field. J Physiol Pharmacol. 2009 ; 60: 57-62
34. Landgraf R, Neumann ID. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front Neuroendocrinol. 2004 ; 25: 150-176
35. Landgraf R, Gerstberger R, Montkowski A, et al. V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities and anxiety-related behavior in rats. J Neurosci. 1995 ; 15: 4250-4258
36. Liebsch G, Wotjak CT, Landgraf R, Engelmann M. Septal vasopressin modulates anxiety-related behaviour in rats. Neurosci Lett. 1996 ; 217: 101-104
37. Manning M, Miteva K, Pancheva S, Stoev S, Wo NC, Chan WY. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with atosiban. Int J Peptide Protein Res. 1995 ; 46: 244-252
38. Mantella RC, Vollmer RR, Li X, et al. Female oxytocin-deficient mice display enhanced anxiety-related behavior. Endocrinology. 2003 ; 144: 2291-2296
39. McCarthy MM, McDonald CH, Brooks PJ, et al. An anxiolytic action of oxytocin is enhanced by estrogen in the mouse. Physiol Behav. 1996 ; 60: 1209-1215
40. Mechaly I, Laurent F, Portet K, Serrano JJ, Cros G. Vasopressin V2 (SR121463A) and V1A (SR49059) receptor antagonists both inhibit desmopressin vasorelaxing activity. Eur J Pharmacol. 1999 ; 383: 287-290
41. Meisenberg G. Short-term behavioral effects of posterior pituitary peptides in mice. Peptides. 1981 ; 2: 1-8
42. Michelini S, Cassano GB, Frare F, Perugi G. Long-term use of benzodiazepines: tolerance, dependence and clinical problems in anxiety and mood disorders. Pharmacopsychiatry. 1996 ; 29: 127-134
43. Neumann ID. Brain oxytocin: a key regulator of emotional and social behaviours in both females and males. J Neuroendocrinol. 2008 ; 20: 585-865
44. Neumann ID, Ludwig M, Engelmann M, Pittman QJ, Landgraf R. Simultaneous microdialysis in blood and brain: oxytocin and vasopressin release in response to central and peripheral osmotic stimulation and suckling in the rat. Neuroendocrinology. 1993 ; 58: 637-645
45. Neumann ID, Kromer SA, Toschi N, Ebner K. Brain oxytocin inhibits the (re)activity of the hypothalamopituitary-adrenal axis in male rats: involvement of hypothalamic and limbic brain regions. Regul Pept. 2000 ; 96: 31-38
46. Nowakowska E, Kus K, Bobkiewicz-Kozlowska T, et al. Role of neuropeptides in antidepressant and memory improving effects of venlafaxine. Polish Journal of Pharmacology. 2002 ; 54: 605-613
47. Pellow S, Chopin P, File SE, Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985 ; 14: 149-167
48. Purba JS, Hoogendijk WJG, Hofman MA, et al. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch Gen Psychiatry. 1996 ; 53: 137-143
49. Ring RH. The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr Pharm Design. 2005 ; 11: 205-225
50. Ring RH, Malberg JE, Potestio L, et al. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology. 2006 ; 185: 218-225
51. Rittig S, Frøkiær J. Basis and therapeutical rationale of the urinary concentrating mechanism. Int J Clin Pract. 2007 ; 61: 2-7
52. Slattery DA, Neumann ID. Chronic icv oxytocin attenuates the pathological high anxiety state of selectively bred Wistar rats. Neuropharmacology. 2010 ; 58: 56-61
53. Soderpalm B, Eriksson E, Engel JA. Anticonflict and rotarod impairing effects of alprazolam and diazepam in rat after acute and subchronic administration. Prog Neuropsychopharmacol Biol Psychiatry. 1989 ; 13: 269-283
54. Stoehr JD, Cramer CP, North WG. Oxytocin and vasopressin hexapeptide fragments have opposing influences on conditioned freezing behavior. Psychoneuroendocrinology. 1992 ; 17: 267-271
55. Treit D. Evidence that tolerance develops to the anxiolytic effect of diazepam in rats. Pharmacol Biochem Behav. 1985 ; 22: 383-387
56. Uvnas-Moberg K. Oxytocin may mediate the benefits of positive social interaction and emotions. Psychoneuroendocrinology. 1998 ; 23: 819-835
57. Uvnäs-Moberg K, Arn I, Magnusson D. The psychobiology of emotion: the role of the oxytocinergic system. Int J Behav Med. 2005 ; 12: 59-65
58. Van Dijk AMA, Lodewijks HMJM, van Ree JM, van Wimersma Greidanus TB. Inhibitory and stimulatory action of vasopressin on the secretion of corticotrophin in rats: structure-activity study. Life Sci. 1981 ; 29: 1107-1116
59. Waldherr M, Neumann ID. Centrally released oxytocin mediates mating-induced anxiolysis in male rats. Proc Natl Acad Sci USA. 2007 ; 104: 16,681-16,684
60. Walf AA, Frye CA. The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nature Protocols. 2007 ; 2: 322-328
61. Windle RJ, Shanks N, Lightman SL, Ingram CD. Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats. Endocrinology. 1997 ; 138: 2829-2834
62. Windle RJ, Kershaw YM, Shanks N, Wood SA, Lightman SL, Ingram CD. Oxytocin attenuates stress-induced c-fos mRNA expression in specific forebrain regions associated with modulation of hypothalamo-pituitary-adrenal activity. J Neurosci. 2004 ; 24: 2974-2982
63. Wotjak CT, Kubota M, Liebsch G, Montkowski A, Holsboer F, Neumann I, Landgraf R. Release of vasopressin within the rat paraventricular nucleus in response to emotional stress: a novel mechanism of regulating adrenocorticotropic hormone secretion?. J Neurosci. 1996 ; 16: 7725-7732
64. Zingg HH. Vasopressin and oxytocin receptors. Baillieres Clin Endocrinol Metab. 1996 ; 10: 75-96